BioTissue

Miami, United States Founded: 2001 • Age: 25 yrs
Regenerative biologic therapies for eye care are developed and provided.
Request Access

About BioTissue

BioTissue is a company based in Miami (United States) founded in 2001 by Amy Tseng and Scheffer CG Tseng. It operates as a Direct-to-Consumer (D2C), and Professional Services. BioTissue has raised $110.04 million across 19 funding rounds from investors including HHS, EW Healthcare Partners and Ballast Point Ventures. BioTissue offers products and services including Prokera, AmnioGraft, Neox 100, and Clarix 100. BioTissue operates in a competitive market with competitors including Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.

  • Headquarter Miami, United States
  • Founders Amy Tseng, Scheffer CG Tseng
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Biotissue
Operational Areas
Healthcare → Medical Devices & Diagnostics
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $110.04 M (USD)

    in 19 rounds

  • Latest Funding Round
    $4.42 M (USD), Grant

    Jun 21, 2021

  • Investors
    HHS

    & 3 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of BioTissue

BioTissue offers a comprehensive portfolio of products and services, including Prokera, AmnioGraft, Neox 100, and Clarix 100. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Used for ocular healing with regenerative tissue technology.

Applied in ocular treatments for tissue regeneration support.

Utilized in surgical procedures for regenerative tissue healing.

Employed in surgical applications for tissue repair solutions.

People of BioTissue
Headcount 200-500
Employee Profiles 64
Board Members and Advisors 5
Employee Profiles
People
Randy Mansfield
Sr. Director, Marketing Content
People
Sergio A. Rodriguez
Sr Manager Of Strategic/national Accounts-biotissue
People
Rodrigo Arbenoiz
Senior Director, Fp&a
People
Angelica Gongora
Sr. People Business Partner

Unlock access to complete

Board Members and Advisors
people
Bob White
Chairman

Unlock access to complete

Funding Insights of BioTissue

BioTissue has successfully raised a total of $110.04M across 19 strategic funding rounds. The most recent funding activity was a Grant round of $4.42 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 19
  • Last Round Grant — $4.4M
  • First Round

    (15 Sep 2006)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2021 Amount Grant - BioTissue Valuation

investors

HHS
Apr, 2019 Amount Series C - BioTissue Valuation EW Healthcare Partners
Nov, 2016 Amount Grant - BioTissue Valuation

investors

HHS
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in BioTissue

BioTissue has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, EW Healthcare Partners and Ballast Point Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
Founded Year Domain Location
Expansion capital is provided by Ballast Point Ventures to growing companies.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by BioTissue

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - BioTissue

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Biotissue Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of BioTissue

BioTissue operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of antibodies to treat complement-mediated neurodegenerative diseases
domain founded_year HQ Location
Drug candidates for immune-mediated diseases are developed by Aldeyra.
domain founded_year HQ Location
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
domain founded_year HQ Location
Mobile SDK developed for app engagement and monetization strategies.
domain founded_year HQ Location
Gene therapies for ocular and neurodegenerative diseases are developed.
domain founded_year HQ Location
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Biotissue

Frequently Asked Questions about BioTissue

When was BioTissue founded?

BioTissue was founded in 2001 and raised its 1st funding round 5 years after it was founded.

Where is BioTissue located?

BioTissue is headquartered in Miami, United States. It is registered at Miami, Florida, United States.

Is BioTissue a funded company?

BioTissue is a funded company, having raised a total of $110.04M across 19 funding rounds to date. The company's 1st funding round was a Grant of $4.42M, raised on Sep 15, 2006.

What does BioTissue do?

BioTissue is engaged in the development and delivery of regenerative healing solutions using human birth tissue products. The company operates in the healthcare sector, specifically within biotechnology and regenerative medicine. Its offerings include ocular and surgical products such as Prokera, AmnioGraft, Neox, and Clarix, which are designed to support tissue repair and healing. Proprietary technologies like CryoTek are utilized to preserve the natural structure and biology of tissues. Research and development efforts are emphasized, with over 40 years of experience and more than 1 million clinical applications recorded.

Who are the top competitors of BioTissue?

BioTissue's top competitors include Annexon, Alimera Sciences and MeiraGTx.

What products or services does BioTissue offer?

BioTissue offers Prokera, AmnioGraft, Neox 100, and Clarix 100.

Who are BioTissue's investors?

BioTissue has 4 investors. Key investors include HHS, EW Healthcare Partners, Ballast Point Ventures, and River Cities Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available